Loading…
PMS-LATANOPROST-TIMOLOL is a brand name for Latanoprost, supplied as a solution. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: AND CLINICAL USE.............................................................................. 3 CONTRAINDICATIONS ................................................................................................... 3 WARNINGS AND PRECAUTIONS…
Verbatim from this product's HC label. Tap a section to expand.
General There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of ocular epithelial surface (see CONSUMER INFORMATION).
There is no or limited experience with latanoprost in inflammatory, neovascular, chronic angle closure or congenital glaucoma, open angle glaucoma in pseudophakic patients and pigmentary glaucoma.
Concomitant therapy:
Latanoprost and timolol maleate may interact with other drugs (see r DRUG INTERACTIONS). The effect on intraocular pressure or the known effects of systemic beta-adrenergic blocking agents may be exaggerated when pms-LATANOPROST-TIMOLOL is given to patients already receiving an oral beta-blocking agent.
The use of two local beta- adrenergic blocking agents is not recommended. There have been reports of paradoxical elevations in IOP following the concomitant ophthalmic administration of two prostaglandin analogs. Therefore, the use of two or more prostaglandins, prostaglandin analogs, or prostaglandin derivatives is not recommended.
Systemic Effects:
Like other topically applied ophthalmic agents, is absorbed systemically. Due to the beta-adrenergic component timolol, the same types of cardiovascular, pulmonary and other adverse reactions seen with systemic beta-adrenergic blocking agents may occur including aggravation of Prinzmetal’s angina, aggravation of peripheral and central circulatory disorders, bradycardia, and hypotension.
Incidence of systemic adverse drug reactions after topical ophthalmic administration is lower than for systemic administration. The systemic absorption can be reduced by using nasolacrimal occlusion or closing the eyelids for 2 minutes (see DOSAGE AND ADMINISTRATION).
Cardiovascular Cardiac reactions:
Death associated with cardiac failure has been reported. Cardiac failure should be adequately controlled before beginning treatment. Patients with a history of severe cardiac disease should be watched for signs of cardiac failure and have their pulse rates checked.
At the first sign of cardiac failure, pms-LATANOPROST-TIMOLOL should be discontinued. Due to its negative effect on conduction time, beta-adrenergic blocking agents should only be given with caution to patients with first degree heart block.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Latanoprost in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
e. severe forms of Raynaud’s disease or Raynaud’s syndrome) should be treated with caution. pms-LATANOPROST-TIMOLOL Product Monograph Page 5 of 30 Endocrine and Metabolism Diabetes Mellitus: Beta-adrenergic blocking agents should be administered with caution in patients subjected to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents.
Beta-adrenergic blocking agents may mask the signs and symptoms of acute hypoglycemia.
Thyrotoxicosis:
Therapy with beta-adrenergic blocking agents may mask certain symptoms of hyperthyroidism. Abrupt withdrawal of beta-adrenergic blocking agent therapy may precipitate a worsening of symptoms. Hepatic/Biliary/Pancreatic Latanoprost and timolol maleate have not been studied in patients with hepatic impairment and therefore should be used with caution in such patients.
g. diplopia, ptosis, generalized weakness). Ophthalmologic Latanoprost has been reported to cause darkening; thickening and lengthening of eye lashes (see ADVERSE REACTIONS). Based on spontaneous reports, very rare cases of darkening of the palpebral skin have been reported with the administration of latanoprost ophthalmic solution (see ADVERSE REACTIONS).
Due to the prostaglandin component latanoprost, pms-LATANOPROST-TIMOLOL should be used with caution in patients with a history of herpetic keratitis. pms-LATANOPROST-TIMOLOL should be avoided in cases of active herpes simplex keratitis and in patients with a history of recurrent herpetic keratitis specifically associated with prostaglandin analogues.
This product contains benzalkonium chloride as a preservative, which may be absorbed by soft contact lenses. Remove contact lenses before administration of pms-LATANOPROST-TIMOLOL. Contact lenses may be reinstalled 15 minutes after administering pms-LATANOPROST- TIMOLOL.
Ophthalmic beta-adrenergic blocking agents may induce dryness of eyes. These agents should be used prescribed with caution in patients with corneal diseases. Macular edema, including cystoid macular edema, has been reported during treatment with latanoprost ophthalmic solution.
These reports have mainly occurred in aphakic patients, in pms-LATANOPROST-TIMOLOL Product Monograph Page 6 of 30 pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema. pms-LATANOPROST-TIMOLOL should be used with caution in these patients.
Choroidal detachment after filtration procedures has been reported with the administration of ocular hypotensive agents.
Changes to Pigmented Tissues:
Latanoprost, the prostaglandin component contained in pms- LATANOPROST-TIMOLOL, may gradually change the eye color, by increasing the amount of brown pigment in the iris. The color change is due to increased melanin content in stromal melanocytes on the iris rather than to an increase in the number of melanocytes.
Typically the brown pigmentation around the pupil spreads concentrically towards the periphery in affected eyes, but the entire iris or parts of it may become more brownish. The change in iris colour occurs slowly and may not be noticeable for several months to years.
The long term effects on the melanocytes and the consequences of potential injury to the melanocytes and/or deposition of […]